DOcumented COVID-19 infection (PCR or CT-scan) more than 3 months before inclusion
Long COVID suspicion with dyspnea (mMRC \> 2 at inclusion)
DLCO \< 75% of predicted value less than 3 months old on the day of screening or to be obtained before Day 1 older than 3 months
You may not be if
Acute COVID-19 infection
Lung scintigraphy and thoracic CT angiography evaluation to rule out pulmonary embolism less than 3 months old on the day of screening or to be obtained before Day 1 if older than 3 months to exclude Sequelae of pulmonary embolism or lung emphysema in the setting of COPD
Women of childbearing potential
Myocardial infarction or stroke less than 3 months before screening
Uncontrolled hypertension (\> 140/90 at inclusion in the study)
Proteinuria/creatinuria ratio \> 1 g/mmol at baseline DFG \< 30 ml/min
History of malignant hypertension
Previous osteonecrosis
History of Aneurysm and artery dissections
Active cancer
Known hypersensitivity to bevacizumab or any ingredient in its formulation, including non-medicinal ingredients, or a component of the container
Hypersensitivity to Chinese Hamster Ovary (CHO) cell product or other recombinant human or humanized antibodies
History of radiotherapy
History of bisphosphonates treatment
Surgery in 28 days before inclusion
Participation in another interventional study or being in the exclusion period at the end of a previous study
Patient unable or unwilling to comply with the follow up schedule (at the investigator's discretion)
Pregnant or breastfeeding women
Vulnerable populations (patient under gardianship, curatorship, deprived of liberty)
